Verona Pharma — Technical Presentation (December 2022)
15 slides from Verona Pharma's technical presentation, Dec 20, 2022
Slide 1: ENHANCE-1 Phase 3 data
ENHANCE - 1 Phase 3 data December 2022 Nasdaq: VRNA | www.veronapharma.com
Slide 2: Forward-looking statements
Forward - looking statements This presentation contains “forward‐looking” statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiary, the “Company”) .. All statements other than stateme
Slide 3: Pivotal Phase 3 program
Pivotal Phase 3 program Two efficacy and safety studies: ENHANCE - 1 and ENHANCE - 2 3 Ensifentrine 3mg BID N=500 Placebo BID N=300 E nsifentrine as a N ovel in HA led N ebulized C OPD th E rapy in moderate to severe COPD ENHANCE - 1 N=800 ENHANCE - 2 N=800 Ensifentrine 3mg BID N=500 Placebo BID N=3
Slide 4: ENHANCE-1 baseline characteristics
ENHANCE - 1 baseline characteristics Demographics and baseline characteristics well balanced between groups 4 Parameter Ensifentrine n=479 Placebo n=284 Total n =763 Age, mean (SD) 65.1 (7.1) 64.9 (7.7) 65.0 (7.4) Gender, % Male, n (%) 275 (57.4) 167 (58.8) 442 (57.9) Moderate / Severe COPD, n (%) M
Slide 5: Primary endpoint met in Phase 3 ENHANCE-1
5 -70 -20 30 80 130 0 1 2 3 4 5 6 7 8 9 10 11 12 FEV 1 mean change from baseline, mL Time post dose, h Ensifentrine 3 mg placebo Primary endpoint met in Phase 3 ENHANCE - 1 Significant and clinically meaningful improvements in lung function at Week 12 5 N=760 Ensifentrine 3 mg placebo +147 mL (p<0.0
Slide 6: Ensifentrine improved lung function in all subgroups
6 Phase 3 ENHANCE - 1 data on file Ensifentrine improved lung function in all subgroups Consistent effects across all subgroups FEV 1 mean change from baseline, mL 0 20 40 60 80 100 120 140 Average FEV 1 AUC 0 - 12h post - dose at Week 12 by Subgroup
Slide 7: Ensifentrine reduced exacerbation rate over 24 weeks
7 Ensifentrine reduced exacerbation rate over 24 weeks 36% reduction in rate of moderate or severe COPD exacerbation vs placebo Treatment Annualized Event Rate LS mean, (95% CI) Rate Ratio (95% CI) Exacerbation Rate Reduction P - value Ensifentrine 3 mg (n = 477) 0.26 (0.17, 0.40) 0.64 (0.40, 1.00)
Slide 8: Ensifentrine significantly delayed time to first exacerbation
Ensifentrine significantly delayed time to first exacerbation 8 38% reduction in risk of a COPD exacerbation Ensifentrine vs. Placebo (N = 760) Hazard Ratio (95%, CI) 0.62 (0.39, 0.97) Risk Reduction 38% P - value 0.0378 477 466 453 431 422 412 404 283 270 258 250 243 235 232 Number at risk Phase 3
Slide 9: Pooled data: significant 40% reduction in exacerbation rate
Pooled data: significant 40% reduction in exacerbation rate Protocol specified pooled analysis including ENHANCE - 1 and ENHANCE - 2 9 Treatment Annualized Event Rate LS mean, (95% CI) Rate Ratio (95% CI) Exacerbation Rate Reduction P - value Ensifentrine 3 mg (n = 975) 0.27 (0.19, 0.39) 0.60 (0.44,
Slide 10: Pooled data: significant 41% risk reduction in time to first exacerbation
Pooled data: significant 41% risk reduction in time to first exacerbation 10 Protocol specified pooled analysis including ENHANCE - 1 and ENHANCE - 2 Ensifentrine vs. Placebo (N = 1,549 ) Hazard Ratio (95%, CI) 0.59 (0.44, 0.81) Risk Reduction 41% P - value 0.0008 975 947 896 853 821 802 784 574 545
Slide 11: Statistically significant improvement in symptoms and QOL
Statistically significant improvement in symptoms and QOL Early and sustained improvement in ENHANCE - 1 11 Symptoms E - RS Total Score by Week (units) (1) Minimal clinically important difference -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Week 6 Week 12 Week 24 MCID (1) -7 -6 -5 -4 -3 -2 -1 0 Week 6 Week 12
Slide 12: Adverse events reported at low rates over 24 and 48 weeks
TEAE: treatment - emergent adverse event 12 Phase 3 ENHANCE - 1 data on file Adverse events reported at low rates over 24 and 48 weeks Few events greater than 1% and greater than placebo in ENHANCE - 1 Event Ensifentrine 3 mg (n = 477) Placebo (n = 283) Subjects with at least one TEAE, n (%) 221 (46
Slide 13: ENHANCE-1 met primary and all key secondary endpoints
ENHANCE - 1 met primary and all key secondary endpoints • Data readout measures 13 Endpoint Top - line Measurement Data Primary endpoint (at Week 12) Average FEV 1 AUC (0 - 12 hours) post dose +87 mL (p<0.0001) vs placebo Secondary endpoints (Lung function at Week 12) (Symptoms / QOL at Week 24) Pea
Slide 14: ENHANCE Program summary
ENHANCE Program summary 14 Top - line Measurement ENHANCE - 1 ENHANCE - 2 Average FEV 1 AUC (0 - 12 hours) +87 mL (p<0.0001) vs placebo +94 mL (p<0.0001) vs placebo Peak FEV 1 +147 mL (p<0.0001) vs placebo +146 mL (p<0.0001) vs placebo Morning Trough FEV 1 +35 mL (p=0.0421) vs placebo +49 mL (p=0.00
Slide 15: Q&A
Q&A Verona Pharma ae Breath of Innovation®
Verona Pharma — Technical Presentation (December 2022) on 6ix